The closure of Bristol Myers Squibb’s viral vector production facility in Libertyville, Illinois, signifies a strategic move to consolidate cell therapy manufacturing operations. This shift to the Devens, Massachusetts facility reflects a cost-effective and scalable manufacturing approach. With a focus on internalizing vector production, the company aims to achieve significant savings through broader restructuring efforts […]
Category: Bristol Myers Squibb
BioNTech’s BNT-327 Halved in $11B+ Deal with BMS
BioNTech has recently forged a significant partnership with Bristol Myers Squibb (BMS), a deal centered on the trade of half of its bispecific compound BNT-327. This deal has the potential to be worth over a staggering $11 billion, marking a major milestone in the biotech industry. This strategic collaboration between these two industry giants is […]
Bristol Myers Squibb, BioNTech Collaborate on Bispecific Antibody for Solid Tumors
Bristol Myers Squibb and BioNTech have announced a strategic collaboration to co-develop and co-commercialize BNT327, an investigational bispecific antibody for numerous solid tumor types. This ground-breaking partnership aims to leverage BioNTech’s innovative approach to expedite clinical trials, reduce time to market, and explore additional potential indications. Coupled with Bristol Myers Squibb’s renowned expertise in delivering […]
BioNTech-Aktie Soars: Bristol Pays Up to $11.1B in Cancer Drug Deal
BioNTech, the Mainz-based biotech company, is set to receive $1.5 billion upfront and $2 billion in installments by 2028 as part of a groundbreaking deal with Bristol Myers Squibb. The partnership also includes up to $7.6 billion in milestone payments, with development, manufacturing costs, and profits to be shared equally between the two companies. This […]
